Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia

Evita Gasenko; Sergejs Isajevs; Maria Constanza Camargo; George Johan A. Offerhaus; Inese Polaka; Margaret L. Gulley; Roberts Skapars; Armands Sivins; Ilona Kojalo; Arnis Kirsners; Daiga Santare; Jelizaveta Pavlova; Olga Sjomina; Elina Liepina; Liliana Tzivian; Charles S. Rabkin; Marcis Leja

doi:10.1097/MEG.0000000000001521

Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia

Evita Gasenko, Sergejs Isajevs, Maria Constanza Camargo, George Johan A. Offerhaus, Inese Polaka, Margaret L. Gulley, Roberts Skapars, Armands Sivins, Ilona Kojalo, Arnis Kirsners, Daiga Santare, Jelizaveta Pavlova, Olga Sjomina, Elina Liepina, Liliana Tzivian, Charles S. Rabkin, Marcis Leja

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Objective Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. Methods Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics was obtained from patient questionnaires, hospital records. Overall survival was ascertained through 30 July 2017. Cox proportional hazard regression models adjusted for personal and tumor-related covariates compared survival between EBV-positive and EBV-negative patients. Results There were a total of 302 gastric cancer patients (61% males) with mean and SD age 63.6 ± 11.5 years. EBER positivity was present in 8.6% of tumors. EBV-positive gastric cancer patients had better survival at 80 months [adjusted hazard ratio = 0.37, 95% confidence interval (CI) = 0.19-0.72] compared to EBV-negative patients. Worse survival was observed for patients with stage III (hazard ratio = 2.76, 95% CI = 1.67-4.56) and stage IV (hazard ratio = 10.02, 95% CI = 5.72-17.57) compared to stage I gastric cancer, and overlapping and unspecified subsite (hazard ratio = 1.85; 95% CI = 1.14; 3.00) compared to distal tumors. Conclusion Tumor EBV positivity is a favorable prognostic factor in gastric cancer.

Original language	English
Pages (from-to)	1328-1333
Journal	European Journal of Gastroenterology and Hepatology
Volume	31
Issue number	11
DOIs	https://doi.org/10.1097/MEG.0000000000001521
Publication status	Published - 1 Nov 2019
Externally published	Yes

Keywords*

Epstein-Barr virus
Epstein-Barr virus-encoded small RNA in-situ hybridization
gastric cancer
survival

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MEG.0000000000001521

Cite this

Gasenko, E., Isajevs, S., Camargo, M. C., Offerhaus, G. J. A., Polaka, I., Gulley, M. L., Skapars, R., Sivins, A., Kojalo, I., Kirsners, A., Santare, D., Pavlova, J., Sjomina, O., Liepina, E., Tzivian, L., Rabkin, C. S., & Leja, M. (2019). Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia. European Journal of Gastroenterology and Hepatology, 31(11), 1328-1333. https://doi.org/10.1097/MEG.0000000000001521

@article{5555ca62a35841d9a57d8c298bfbbce8,

title = "Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia",

abstract = "Objective Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. Methods Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics was obtained from patient questionnaires, hospital records. Overall survival was ascertained through 30 July 2017. Cox proportional hazard regression models adjusted for personal and tumor-related covariates compared survival between EBV-positive and EBV-negative patients. Results There were a total of 302 gastric cancer patients (61% males) with mean and SD age 63.6 ± 11.5 years. EBER positivity was present in 8.6% of tumors. EBV-positive gastric cancer patients had better survival at 80 months [adjusted hazard ratio = 0.37, 95% confidence interval (CI) = 0.19-0.72] compared to EBV-negative patients. Worse survival was observed for patients with stage III (hazard ratio = 2.76, 95% CI = 1.67-4.56) and stage IV (hazard ratio = 10.02, 95% CI = 5.72-17.57) compared to stage I gastric cancer, and overlapping and unspecified subsite (hazard ratio = 1.85; 95% CI = 1.14; 3.00) compared to distal tumors. Conclusion Tumor EBV positivity is a favorable prognostic factor in gastric cancer.",

keywords = "Epstein-Barr virus, Epstein-Barr virus-encoded small RNA in-situ hybridization, gastric cancer, survival",

author = "Evita Gasenko and Sergejs Isajevs and Camargo, {Maria Constanza} and Offerhaus, {George Johan A.} and Inese Polaka and Gulley, {Margaret L.} and Roberts Skapars and Armands Sivins and Ilona Kojalo and Arnis Kirsners and Daiga Santare and Jelizaveta Pavlova and Olga Sjomina and Elina Liepina and Liliana Tzivian and Rabkin, {Charles S.} and Marcis Leja",

note = "Funding Information: Project No. LZP-2018/1-0135 {\textquoteleft}Research on implementation of a set of measures for prevention of gastric cancer mortality by eradication of H. pylori and timely recognition of precancerous lesions{\textquoteright} of the Latvian Council of Research. This study was supported in part by the Intramural Research Program, US National Cancer Institute. Publisher Copyright: {\textcopyright} 2019 Lippincott Williams and Wilkins. All rights reserved.",

year = "2019",

month = nov,

day = "1",

doi = "10.1097/MEG.0000000000001521",

language = "English",

volume = "31",

pages = "1328--1333",

journal = "European Journal of Gastroenterology and Hepatology",

issn = "0954-691X",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

Gasenko, E, Isajevs, S, Camargo, MC, Offerhaus, GJA, Polaka, I, Gulley, ML, Skapars, R, Sivins, A, Kojalo, I, Kirsners, A, Santare, D, Pavlova, J, Sjomina, O, Liepina, E, Tzivian, L, Rabkin, CS & Leja, M 2019, 'Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia', European Journal of Gastroenterology and Hepatology, vol. 31, no. 11, pp. 1328-1333. https://doi.org/10.1097/MEG.0000000000001521

TY - JOUR

T1 - Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia

AU - Gasenko, Evita

AU - Isajevs, Sergejs

AU - Camargo, Maria Constanza

AU - Offerhaus, George Johan A.

AU - Polaka, Inese

AU - Gulley, Margaret L.

AU - Skapars, Roberts

AU - Sivins, Armands

AU - Kojalo, Ilona

AU - Kirsners, Arnis

AU - Santare, Daiga

AU - Pavlova, Jelizaveta

AU - Sjomina, Olga

AU - Liepina, Elina

AU - Tzivian, Liliana

AU - Rabkin, Charles S.

AU - Leja, Marcis

N1 - Funding Information: Project No. LZP-2018/1-0135 ‘Research on implementation of a set of measures for prevention of gastric cancer mortality by eradication of H. pylori and timely recognition of precancerous lesions’ of the Latvian Council of Research. This study was supported in part by the Intramural Research Program, US National Cancer Institute. Publisher Copyright: © 2019 Lippincott Williams and Wilkins. All rights reserved.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Objective Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. Methods Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics was obtained from patient questionnaires, hospital records. Overall survival was ascertained through 30 July 2017. Cox proportional hazard regression models adjusted for personal and tumor-related covariates compared survival between EBV-positive and EBV-negative patients. Results There were a total of 302 gastric cancer patients (61% males) with mean and SD age 63.6 ± 11.5 years. EBER positivity was present in 8.6% of tumors. EBV-positive gastric cancer patients had better survival at 80 months [adjusted hazard ratio = 0.37, 95% confidence interval (CI) = 0.19-0.72] compared to EBV-negative patients. Worse survival was observed for patients with stage III (hazard ratio = 2.76, 95% CI = 1.67-4.56) and stage IV (hazard ratio = 10.02, 95% CI = 5.72-17.57) compared to stage I gastric cancer, and overlapping and unspecified subsite (hazard ratio = 1.85; 95% CI = 1.14; 3.00) compared to distal tumors. Conclusion Tumor EBV positivity is a favorable prognostic factor in gastric cancer.

AB - Objective Epstein-Barr virus (EBV)-associated gastric cancer has been proposed to be a distinct gastric cancer molecular subtype. The prognostic significance of EBV infection in gastric cancer remains unclear and needs further investigation. Our study aimed to analyze EBV-positive and EBV-negative gastric cancer patients regarding their personal and tumor-related characteristics, and compare their overall survival. Methods Gastric cancer patients consecutively treated at the Riga East University Hospital during 2009-2016 were identified retrospectively. Tumor EBV status was determined by in-situ hybridization for EBV-encoded RNA (EBER). Information about clinicopathological characteristics was obtained from patient questionnaires, hospital records. Overall survival was ascertained through 30 July 2017. Cox proportional hazard regression models adjusted for personal and tumor-related covariates compared survival between EBV-positive and EBV-negative patients. Results There were a total of 302 gastric cancer patients (61% males) with mean and SD age 63.6 ± 11.5 years. EBER positivity was present in 8.6% of tumors. EBV-positive gastric cancer patients had better survival at 80 months [adjusted hazard ratio = 0.37, 95% confidence interval (CI) = 0.19-0.72] compared to EBV-negative patients. Worse survival was observed for patients with stage III (hazard ratio = 2.76, 95% CI = 1.67-4.56) and stage IV (hazard ratio = 10.02, 95% CI = 5.72-17.57) compared to stage I gastric cancer, and overlapping and unspecified subsite (hazard ratio = 1.85; 95% CI = 1.14; 3.00) compared to distal tumors. Conclusion Tumor EBV positivity is a favorable prognostic factor in gastric cancer.

KW - Epstein-Barr virus

KW - Epstein-Barr virus-encoded small RNA in-situ hybridization

KW - gastric cancer

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85072771903&partnerID=8YFLogxK

U2 - 10.1097/MEG.0000000000001521

DO - 10.1097/MEG.0000000000001521

M3 - Article

C2 - 31569122

AN - SCOPUS:85072771903

SN - 0954-691X

VL - 31

SP - 1328

EP - 1333

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

IS - 11

ER -

Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia

Abstract

Keywords*

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this